Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 535-540

  Nomura, Shosaku ^a   Taniura, Takehito ^b   Shouzu, Akira ^c   Omoto, Seitarou ^a   Inami, Norihito ^a   Fujita, Shinya ^a   Tamaki, Takeshi ^a   Yokoi, Takashi ^a   Shimizu, Toshiki ^a   Ito, Tomoki ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Ueda Hospital   (Japan)

^c Saiseikai Izuo Hospital   (Japan)

Author keywords

Adiponectin; Atherothrombosis; Hyperlipidemia; PAI 1; Pitavastatin

Indexed keywords

ADIPONECTIN; CD40 LIGAND; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SOLUBLE CD40 LIGAND; SOLUBLE P SELECTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PLATELET MICROPARTICLE; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION;

EID: 84873447434     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S31346     Document Type: Article

References (45)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Croft KD, Beilin LJ, Vandongen R, Rouse I, Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia. Atherosclerosis. 1990;83:101-109.
3. Chobanian AV. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia co-exist. Hypertension. 1991;18:130-131.
4. Fogelman A, Schechter I, Seager J, et al. Malondialdehyde alteration of low density lipoproteins leads to chelesterylester accumulation in macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
5. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherosclerotic plaque. Atherosclerosis. 1994;105:1-7.
6. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Artherioscler Thromb Vasc Biol. 2003;23:1979-1989.
7. Zhao R, Ma X, Xie X, Shen GX. Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1in vascular endothelial cells. Am J Physiol Endocrino Metab. 2009;297:E104-E111.
8. Kuniyasu A, Tokunaga M, Yamamoto T, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes. Biochim Biophys Acta. 2011;1811:153-162.
9. Shen GX. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. Int J Mol Med. 1998;1:399-408.
10. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
11. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
12. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patients. Artherioscler Thromb Vasc Biol. 2000;20:1595-1599.
13. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
14. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021-45026.
15. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 2003;46:1543-1549.
16. Scandinavian Simbvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
17. West of Scotland Coronary Prevention Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
18. Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212:131-138.
19. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157-164.
20. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-bind, three-group parallel comparison. Arzeimittelforschung. 2002;52:251-255.
21. Han J, Zhou X, Yokoyama T, et al. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation. 2004;109:790-796.
22. Kawakami A, Tani M, Chiba T, et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through apoB48 receptor-dependent mechanism. Artherioscler Thromb Vasc Biol. 2005;25:424-429.
23. Wang J, Tokoro T, Matsui K, Higa S, Kitajima J. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Scien. 2005;76:2257-2268.
24. The Expert Committee on the Guideline for Diagnosis and Treatment of Hyperlipidemia. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemia, Japan Atherosclerosis Society (JAS): Guideline for Diagnosis and Treatment of Hyperlipidemias in Adults. Doumyakukouka. 1997;25:1-34.
25. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ECDCDM). Report of the expert commitee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; (26 Suppl 1):S5-S20.
26. Osumi K, Ozeki Y, Saito S, et al. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost. 2001;85:326-330.
27. Nomura S, Uehata S, Saito S, et al. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost. 2003;89:506-512.
28. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
29. Carmelier P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1in arterial healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
30. Ma GM, Halayko AJ, Stelmack GL, et al. Effects of oxidized and glycated low-density lipoprotections on transcription and secretion of plasminogen activator inhibitor-1in vascular endothelial cells. Cardiovasc Pathol. 2006;15:3-10.
31. Dichtl W, Stiko A, Eriksson P, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Artherioscler Thromb Vasc Biol. 1999;19:3025-3032.
32. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsly MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation. 2002;106: 2372-2378.
33. Lautamäki R, Rönnemaa T, Huupponen R, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007;56:881-886.
34. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macropages. Circulation. 2001;103:1057-1063.
35. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47-50.
36. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236-3240.
37. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2006;414:813-820.
39. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drug Today. 2004;40:975-990.
40. Zeng L, Xu H, Chew TL, et al. Simvastatin modulates angiotensin II signaling pathway by preventing Rac 1-mediated upregulation of p27. J Am Soc Nephrol. 2004;15:1711-1720.
41. Hogue JC, Lamarche B, Tremblay AJ, et al. Differntial effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism. 2008;57:380-386.
42. Song CY, Kim BC, Lee HS. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming groth factor-β1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells. Transl Res. 2008; 151:27-35.
43. Inami N, Nomura S, Shouzu A, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007-2008;36:1-8.
44. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122:39-45.
45. Erol A. The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins-statins activate the generation of metabolically more capable adipocytes. Med Hypotheses. 2005;64:69-73.